MedDataX Logo

The Effect of Message Framing on Blood Donation-Study 1

NCT03741413 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2074

Last updated 2020-05-05

No results posted yet for this study

Summary

Rh negative blood group is a rare blood group in China, as it only accounts for 0.3-0.4 percent of the Han population. Therefore, low inventory is often found in blood collection and supply agencies in many regions in China. On July 18, 2018 blood stockpile of O-negative and B-negative in Guangzhou Blood Center reached the warning line, and we took measures for emergency recruitment. O-negative and B-negative blood donors whose last donation dates were between January 1, 2015 and December 31, 2017 were identified and randomly assigned to three groups. Three different recruitment text messages were send to these groups respectively. At the same time, A-negative and AB-negative blood donors were marked as control group. We observed the re-donation rates among four groups within three months.

Conditions

  • Rh Negative Blood Donor

Interventions

OTHER

Gain-frame SMS

Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.

OTHER

Loss-frame SMS

Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.

OTHER

Control SMS

Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.

Sponsors & Collaborators

  • Guangzhou Blood Center

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-18
Primary Completion
2018-10-18
Completion
2018-10-18

Countries

  • China

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03741413 on ClinicalTrials.gov